There is no cure for osteoporosis but antiresorptive drugs can reduce further bone loss and slow down disease progression. This report provide information on both the individual and community use of antiresorptive drugs for managing osteoporosis as well as trends in the supply of and expenditure for these medications.
ISBN 978-1-74249-192-9; Cat. no. PHE 148; 48pp.; Internet Only
Publication table of contents
- Preliminary material
- Title and verso pages
- Body section
- What is osteoporosis?
- The extent of the problem
- Osteoporosis and bone remodelling
- Antiresorptives available in 2003–07
- Compliance with antiresorptive therapy
- Questions addressed in this study
- Structure and aims of the report
- The study design
- Pharmaceutical Benefits Scheme
- Antiresorptives monitored
- Cohort selection
- Initiation of antiresorptive therapy
- Demographic characteristics of initiating cohort
- The first prescribed antiresorptive
- Time taken to fill the first prescription
- The first 12 months of antiresorptive supply
- How many prescribers?
- Drug switching
- Were enough antiresorptives supplied in the first 12 months?
- End matter
- Appendix A PBS data
- Appendix B The study cohorts
- List of tables
- List of figures
AIHW 2011. Use of antiresorptive agents for osteoporosis management. Cat. no. PHE 148. Canberra: AIHW. Viewed 27 March 2017 <http://www.aihw.gov.au/publication-detail/?id=10737419752>.